AKT1 and breast carcinoma: We collected an expression dataset of 45 breast cancer cell lines, for which a drug sensitivity screen, with − log10GI50 scores, for over 70 drugs had also been performed [16], including known AKT inhibitors (Sigma1.2 and triciribine), PI3K inhibitors (TGX221, GSK2119563, GSK1059615 and AS.252424), mTOR inhibitors (rapamycin and temsirolimus) and dual PI3K/mTOR inhibitors (GSK2126458 and BEZ235).